Home-Conexeu Debuts on Nasdaq With Preclinical Regenerative Tissue Platform
Conexeu Sciences, a preclinical-stage regenerative tissue platform company, debuted onNasdaq, framing the public listing as a milestone for its mission of “Architecting Bioregeneration” and for the development of a platform designed to support the biological conditions needed to restore lost or damaged tissue.
“At Conexeu, we believe regenerative medicine requires more than incremental improvement; it requires a fundamentally different foundation,” said Miles D. Harrison, President and CEO of Conexeu. “We believe we are building the biological architecture for a new generation of regenerative medicine designed not simply to replace what has been lost, but to help the body restore itself. Becoming a public company we believe strengthens our ability to continue advancing the science, infrastructure, and platform capabilities behind that long-term mission.”
Recent product development includesBIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE(B.R.E.A.S.T.), a 3D bioprinted regenerative breast matrix intended to support the body’s own tissue regeneration following mastectomy. Built with the proprietary CXU platform, the matrix is designed to serve as a temporary regenerative scaffold that gradually resorbs as the patient’s tissue remodels and replaces it over time. Conexeu described that approach as a possible shift from permanent implants or traditional reconstruction methods. More than 100,000 women undergo mastectomies annually in the U.S., while many do not pursue reconstruction.
“Today marks an important milestone in Conexeu’s evolution as we enter the public markets during an important period of advancement across regenerative medicine, biomaterials science, and tissue restoration,” said Jeff Sharpe, Chairman of the Board of Directors. “We believe this step will enhance the Company’s ability to expand development initiatives, increase visibility within the regenerative medicine sector and continue advancing its platform across multiple potential applications.”
CXU, the company’s patented bioregenerative extracellular matrix platform, is built on what Conexeu describes as a single structural principle: one formula, one device, designed to scale across multiple addressable markets without reformulation. Its lead product, Ten Minute Tissue, is a CXU-based injectable extracellular matrix that remains fluid at room temperature and transitions to a stable gel in situ at body temperature in about ten minutes. In preclinical studies, Ten Minute Tissue demonstrated enhanced healing dynamics, organized scaffold formation, and a low inflammatory profile, supporting cell migration, proliferation, differentiation, and new tissue formation.
The platform is based on more than a decade of university preclinical research and is protected by issued patents in the U.S., E.U., Japan, and Australia, with additional filings pending. Conexeu holds all rights, title, and interest in the platform’s intellectual property, with no royalty or licensing obligations, and states that it has the freedom to expand into new indications and markets. Target markets include wound care, periodontal applications, facial and body contouring, GLP-1-related skin laxity, 3D printing and biofabrication workflows, and veterinary applications. A predicate-based U.S. regulatory strategy is underway, with a 510(k) submission planned for early 2027 for the initial indication, subject to regulatory review.
3D printed breast scaffolds remain early but are gaining clinical and strategic backing
Breast reconstruction scaffoldsproduced through 3D printing and bioprintinghave drawn investment as developers look for alternatives to permanent implants.Tiger Aesthetics Medical, part ofTiger Biosciences, recently invested inGenesisTissue, a US biotechnology company developing personalized 3D bioprinting technology for lumpectomy, mastectomy, and cosmetic reconstruction. GenesisTissue’s lead program centers on a degradable scaffold designed to provide structural support after implantation and then resorb as tissue replaces it, placing Conexeu’s breast matrix within a broader push toward temporary regenerative structures rather than permanent implantable devices.
Clinical evidence in this category remains limitedand investigational.BellaSeno, a German medical startup, recently reported one-year results from Australian trials involving 19 breast augmentation revision patients and 7 patients treated for pectus excavatum using resorbable polycaprolactone scaffolds. All participants completed follow-up with no major scaffold-related complications and no cases requiring removal, while the company said a final two-year follow-up is due next year and pivotal studies in the US and Europe are planned. That leaves the field with encouraging early signals, but not long-term proof or broad regulatory clearance.
Source: 3D Printing Industry
